WST - Chad Winters Expands Holdings With West Pharmaceutical Servs Stock Options | Benzinga
In a recent SEC filing, it was disclosed that Chad Winters, VP at West Pharmaceutical Servs (NYSE:WST), made a noteworthy acquisition of company stock options on February 22,.
What Happened: Winters, VP at West Pharmaceutical Servs, engaged in a derivative transaction according to a Form 4 filing on Thursday with the U.S. Securities and Exchange Commission. This involved the acquisition of stock options for 1,020 shares of WST, providing the right to purchase the company's stock at an exercise price of $350.18 per share.
During Friday's morning session, West Pharmaceutical Servs shares down by 0.0%, currently priced at $359.9. Considering the current price, Winters's 1,020 shares have a total value of $9,914.
Get to Know West Pharmaceutical Servs Better
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
West Pharmaceutical Servs's Economic Impact: An Analysis
Positive Revenue Trend: Examining West Pharmaceutical Servs's financials over 3 ...